1-3 of 3
Eric Kuo
Close
Sort by
Journal Articles

Phase 1b/2 Trial of Enasidenib in Lower-Risk MDS and Nonproliferative CMML without Isocitrate Dehydrogenase Type 2 Mutations

Eric Kuo, Veronica Santiago, Kailee Tanaka, Vikram Puram, Crystal Zhou, Jesse W. Tai, Gabriel Mannis, Ravindra Majeti, Tian Y. Zhang
Journal: Blood
Blood (2023) 142 (Supplement 1): 1879.
https://doi.org/10.1182/blood-2023-187644
Published: 2023
Journal Articles

Monitoring Measurable Residual Disease Using Peripheral Blood in Acute Lymphoblastic Leukemia: Results of a Prospective, Observational Study

Lori S. Muffly, MD MS, Vandana Sundaram, MPH, Connie Chen, Ilana Yurkiewicz, MD BS, Eric Kuo, Sarah Burnash, Jay Y. Spiegel, MDFRCPC, Kelly Chyan, Sally Arai, MD MS, Matthew J. Frank, MD PhD, Laura J. Johnston, MD, Robert Lowsky, MD FRCP, Everett H Meyer, MD PhD, Robert S. Negrin, MD, Andrew R. Rezvani, MD, Surbhi Sidana, MD, Parveen Shiraz, MD, Judith A Shizuru, MD PhD, Wen-Kai Weng, MD PhD, Michaela Liedtke, MD, Hyma T. Vempaty, MD, David B. Miklos, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 22–23.
https://doi.org/10.1182/blood-2020-138988
Published: 2020
Journal Articles

Real World Outcomes of Adult B-Cell Acute Lymphocytic Leukemia Patients Treated with Inotuzumab Ozogamicin

Talha Badar, MD, Aniko Szabo, PhD, Martha Wadleigh, MD, Michaela Liedtke, MD, Shukaib Arslan, MD, Caitlin Siebenaller, PharmD, Ibrahim Aldoss, MD, Elizabeth Schultz, Mehrdad Hefazi, MD, Mark Litzow, MD, Eric Kuo, Amy Wang, MD MPH, Emily K Curran, MD, Rory M Shallis, MD, Nikolai A. Podoltsev, MD PhD, Suresh Kumar Balasubramanian, MD, Jay Yang, MD, Ryan J. Mattison, MD, Madelyn Burkart, MD, Shira Dinner, Anjali S. Advani, MD, Ehab L. Atallah, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1302.
https://doi.org/10.1182/blood-2019-124882
Published: 2019